VERZONI, ELENA
 Distribuzione geografica
Continente #
EU - Europa 1.672
NA - Nord America 993
AS - Asia 355
OC - Oceania 9
SA - Sud America 8
AF - Africa 2
Totale 3.039
Nazione #
US - Stati Uniti d'America 981
DE - Germania 877
GB - Regno Unito 365
CN - Cina 164
SE - Svezia 150
IT - Italia 127
SG - Singapore 60
IE - Irlanda 45
FI - Finlandia 36
IN - India 33
FR - Francia 32
HK - Hong Kong 30
JP - Giappone 22
KR - Corea 22
AU - Australia 9
CA - Canada 9
ID - Indonesia 9
UA - Ucraina 6
BE - Belgio 5
NL - Olanda 5
BR - Brasile 4
RU - Federazione Russa 4
AT - Austria 3
CH - Svizzera 3
CO - Colombia 3
ES - Italia 3
MX - Messico 3
TR - Turchia 3
TW - Taiwan 3
GR - Grecia 2
MY - Malesia 2
VN - Vietnam 2
AR - Argentina 1
BG - Bulgaria 1
DK - Danimarca 1
EE - Estonia 1
IL - Israele 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
LI - Liechtenstein 1
MD - Moldavia 1
ME - Montenegro 1
NO - Norvegia 1
NP - Nepal 1
PK - Pakistan 1
PL - Polonia 1
SI - Slovenia 1
TN - Tunisia 1
Totale 3.039
Città #
Frankfurt am Main 819
Southend 332
Chandler 195
Milan 84
Fairfield 82
Ashburn 78
Seattle 68
Wilmington 68
Princeton 60
Dublin 45
Houston 36
Woodbridge 34
Munich 33
Cambridge 31
Nanjing 30
Singapore 30
Hong Kong 29
New York 29
Beijing 24
Dearborn 24
Bengaluru 18
Shanghai 14
Ann Arbor 13
Des Moines 13
Phoenix 13
Helsinki 12
Redwood City 12
Eitensheim 11
London 11
Jakarta 9
Shenyang 8
Hangzhou 7
Hebei 7
Tokyo 7
Changsha 6
Jinan 6
Nanchang 6
Silver Spring 6
Toronto 6
Zhengzhou 6
Chicago 5
Guangzhou 5
Jiaxing 5
Los Angeles 5
San Diego 5
Brussels 4
Fremont 4
Hyderabad 4
Norwalk 4
Tianjin 4
Boardman 3
Bogotá 3
Grafing 3
San Francisco 3
Seoul 3
São Paulo 3
Vienna 3
Amsterdam 2
Athens 2
Berlin 2
Fuzhou 2
Guwahati 2
Hanoi 2
Hefei 2
Herne 2
Kuala Lumpur 2
Matsumicho 2
Medford 2
Mexico City 2
Petoskey 2
Pioltello 2
Rho 2
Rome 2
San Jose 2
Sandwich 2
Taiyuan 2
Wuhan 2
Zurich 2
Acton 1
Aizawl 1
Akita 1
Amman 1
Ankara 1
Arcadia 1
Arnhem 1
Bad Muenstereifel 1
Barcelona 1
Boisbriand 1
Brooklyn 1
Burlingame 1
Burwood 1
Canberra 1
Central 1
Charlotte 1
Chennai 1
Chisinau 1
Cincinnati 1
Cleveland 1
Concesio 1
Davis 1
Totale 2.452
Nome #
Cabozantinib in the treatment of advanced renal cell carcinoma : Design, development, and potential place in the therapy 202
Targeted treatments in advanced renal cell carcinoma : focus on Axitinib 173
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? 158
Clinical impact of Pancreatic metastases from renal cell carcinoma : A multicenter retrospective analysis 157
Butterfly and renal cell cancer : Out of chaos comes order 138
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors 129
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 127
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 125
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases 119
Treatment of collecting duct carcinoma : current status and future perspectives 116
From biology to clinical experience : evolution in the knowledge of neuroendocrine tumours 114
Safety profile and treatment response of everolimus in different solid tumors : an observational study 107
Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors 106
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies : overall results from a large cohort of patients 102
First line treatment of metastatic renal cell carcinoma : two standards with different toxicity profile 97
Patient approach in advanced/metastatic renal cell carcinoma : focus on the elderly population and treatment-related toxicity 97
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma : a systematic review and meta-analysis of literature data 97
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer : a systematic review and meta-analysis 97
Immunotherapy advances in uro-genital malignancies 97
Study design and clinical evidence in mRCC : can we save axitinib as a first-line therapy? 94
Treatment of elderly patients with metastatic renal cell carcinoma 90
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib 88
Rationale and protocol of SOAP : A phase II study to evaluate the efficacy of Sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma 81
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma : results from a large cohort of patients 77
Biomarker-driven immunotherapy for precision medicine in prostate cancer 77
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 72
Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients 70
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents 69
Management of advanced genitourinary tumors 62
Prognostic role of pancreatic metastases from renal cell carcinoma : Results from an Italian center 56
Targeted therapies and survival: What we can learn from studies in advanced renal cell carcinoma 36
Totale 3.230
Categoria #
all - tutte 7.803
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.803


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020303 46 16 11 31 17 34 32 24 38 30 11 13
2020/2021196 19 16 10 10 25 24 9 11 39 11 8 14
2021/2022276 15 12 8 7 9 12 11 22 14 29 12 125
2022/2023527 52 93 61 65 33 84 17 25 63 6 26 2
2023/20241.025 5 23 29 6 95 9 160 161 67 148 162 160
2024/202571 71 0 0 0 0 0 0 0 0 0 0 0
Totale 3.230